Pharmaceutical scientist charged with insider trading linked to CVS Health acquisition

livemint.com

A pharmaceutical scientist, Carlos Sacanell, faces charges for insider trading after allegedly profiting $617,000 from a tip about CVS Health's acquisition of Oak Street Health. His domestic partner, an Oak Street executive, provided the confidential information. Sacanell was indicted in Philadelphia for insider trading and lying to investigators. He pleaded not guilty and was released on bond. The SEC also filed a lawsuit against him. The CVS deal, valued at $10.6 billion, was announced on February 8, 2023. Prosecutors claim Sacanell was the largest trader of Oak Street options just before the announcement, despite not trading the stock for two years prior.


With a significance score of 2.4, this news ranks in the top 13% of today's 23358 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Pharmaceutical scientist charged with insider trading linked to CVS Health acquisition | News Minimalist